Back to search

University of Sheffield

Development and Application of Ion Pair Reverse Phase HPLC for the Analysis of DNA Aptamers, dsRNA Biocontrols and mRNA Therapeutics

Abstract

dc:description.abstract

Nucleic acids are emerging as a powerful new class of therapeutic and play an increasingly important role in biotechnology. The global mRNA therapeutic market alone is expected to reach $128.14 billion by 2030. mRNA vaccines significantly reduce vaccine development time due to their ease of customisation, and DNA/RNA aptamers are emerging as potential therapeutics and have broader applications in biotechnology. dsRNA biopesticides are also emerging as novel sustainable pesticides. However, each of these faces unique challenges; while dsRNA biocontrols such as Ledprona have been successfully deployed and mRNA vaccines proved vital during the COVID pandemic, they are subject to strict regulations and quality control. Robust analytical methods are required to fully characterise these biomolecules to support manufacturing and ensure their safety and efficacy. ssDNA aptamers are currently developed using in vitro selection (SELEX). However, high failure rates can impact the development and generation of new aptamers. This study aimed to develop and utilise ion pair reverse phase HPLC (IP RP HPLC) to analyse and characterise mRNA therapeutics and dsRNA biocontrols. In addition, it was proposed that the SELEX procedure be optimised before generating ssDNA aptamers for the melanoma differentiation-associated gene-9 (MDA-9). IP RP HPLC was used under denaturing conditions to develop a novel method for the isolation of ssDNA in SELEX. The novel method enabled the rapid purification of ssDNA with an 80% yield, demonstrating significant advantages over existing methods. This method was subsequently utilised in SELEX to obtain ssDNA aptamers to Syntenin-1. Modifications to the SELEX approach resulted in the successful generation of ssDNA aptamers against Syntenin-1. Binding affinity studies demonstrated that the ssDNA aptamers had binding affinities in the 100- 600 nM range, with the highest affinity aptamer at 25 nM. IP RP HPLC was also developed to accurately size dsRNA biocontrols and mRNA therapeutics. A wide range of ion pair reagents were studied under denaturing and nondenaturing conditions. The results showed that accurate sizing of a range of dsRNA biocontrols resulted in less than 2.5% error using dibutyl ammonium acetate in the mobile phase. The IP RP HPLC methods developed in this thesis offer significant advantages over existing methods for generating ssDNA and accurately sizing dsRNA biocontrols. In addition, further work building on the ssDNA aptamers against Syntenin-1 could develop novel therapeutics as inhibitors to a protein important to cancer proliferation.

Degree

thesis:*
Name dc:type.qualificationname
Ph.D
Level dc:type.qualificationlevel
doctoral
Grantor dc:publisher.institution
University of Sheffield
Year dc:date.issued
2024

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Coombes, Paul Edward
Advisor dc:contributor.advisor
  • Dickman, Mark

Rights

Language dc:language.dcterms_iso639_2
eng

Chain of custody

source
Harvested from
White Rose University Consortium
Base URL
etheses.whiterose.ac.uk/cgi/oai2
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
related terms
citation

Coombes, Paul Edward. Development and Application of Ion Pair Reverse Phase HPLC for the Analysis of DNA Aptamers, dsRNA Biocontrols and mRNA Therapeutics. doctoral thesis, University of Sheffield, 2024.